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Abstract
Background: A public health response is essential to meet the multidimensional needs of patients and families
affected by HIV disease in sub-Saharan Africa. In order to appraise curret provision of HIV care and support in East
Africa, and to provide evidence-based direction to future care programming, and Public Health Evaluation was
commissioned by the PEPFAR programme of the US Government.
Methods/Design: This paper described the 2-Phase international mixed methods study protocol utilising
longitudinal outcome measurement, surveys, patient and family qualitative interviews and focus groups, staff
qualitative interviews, health economics and document analysis.
Aim 1) To describe the nature and scope of HIV care and support in two African countries, including the types of
facilities available, clients seen, and availability of specific components of care [Study Phase 1]. Aim 2) To determine
patient health outcomes over time and principle cost drivers [Study Phase 2].
The study objectives are as follows. 1) To undertake a cross-sectional survey of service configuration and activity by
sampling 10% of the facilities being funded by PEPFAR to provide HIV care and support in Kenya and Uganda
(Phase 1) in order to describe care currently provided, including pharmacy drug reviews to determine availability
and supply of essential drugs in HIV management. 2) To conduct patient focus group discussions at each of these
(Phase 1) to determine care received. 3) To undertake a longitudinal prospective study of 1200 patients who are
newly diagnosed with HIV or patients with HIV who present with a new problem attending PEPFAR care and
support services. Data collection includes self-reported quality of life, core palliative outcomes and components of
care received (Phase 2). 4) To conduct qualitative interviews with staff, patients and carers in order to explore and
understand service issues and care provision in more depth (Phase 2). 5) To undertake document analysis to
appraise the clinical care procedures at each facility (Phase 2). 6) To determine principle cost drivers including staff,
overhead and laboratory costs (Phase 2).
Discussion: This novel mixed methods protocol will permit transparent presentation of subsequent dataset results
publication, and offers a substantive model of protocol design to measure and integrate key activities and
outcomes that underpin a public health approach to disease management in a low-income setting.
Background
Within Sub-Saharan Africa during 2007 There were an
estimated 22 million individuals living with HIV infec-
tion, 1.5 million HIV-related deaths, and 11.6 million
children orphaned due to parental HIV infection [1]. A
public health approach is clearly required to provide
appropriate health care to meet the preventive, care and
support, treatment, and bereavement needs associated
with the epidemic. In terms of domains of interest for a
public health approach, the endpoints must include
both the patient and their informal carers and family.
This is particularly true in resource limited settings
where progressive disease compounds family-wide pov-
erty, and where a limited health sector relies on infor-
mal caregivers to provide both inpatient and home care.
Further, we must determine the effectiveness of inter-
ventions across the multiple dimensions of need that
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underpin the lived experience of disease, i.e. the physical
(e.g. virological responses, symptoms and treatment side
effects), psychological (e.g. anxiety and depression),
social (family needs, food security and stigma) and spiri-
tual needs (e.g. finding peace and comfort through spiri-
tual care). These domains are inextricably linked, and
arguably cannot be effectively addressed in isolation.
In 2003 the United States government (USG) funded a
five-year, $15 billion initiative to combat the global HIV/
AIDS epidemic: the President’s Emergency Plan for AIDS
Relief (PEPFAR). The funds were allocated approximately
as follows: treatment (55%), prevention (20%), assisting
orphans and vulnerable children (10%) and care and
support of individuals with HIV/AIDS (15%) for years
2003-2008. In 2008, PEPFAR was reauthorized for a
further five years up to $48 billion.
Evaluation of the effect of PEPFAR funding in its tar-
get countries has established that there has been a
decrease in HIV-related deaths [2], and a reduction in
the number of HIV positive births [3]. While the focus
on increased access to treatment has achieved results,
there has been a lack of evidence for the effectiveness of
care and support on patient and family self-report out-
comes such as quality of life, or on evaluation of the
models of care being delivered. Lack of attention to
these outcomes may undermine and diminish the gains
brought by improved treatment access. Person-centred
self report measures are essential as there is an increas-
ing body of evidence that people living with HIV infec-
tion endure multiple distressing problems from the
point of diagnosis and alongside treatment [4], including
suicidal ideation [5], depression [6,7], fatigue [8], pov-
erty, malnutrition [9], pain [10] and other symptoms
[11], poor access to symptom controlling drugs [12],
spiritual distress [13] and information needs [14].
In order to evaluate funded programmes, and to facili-
tate evidence-based programming of the funding
response, Public Health Evaluations (PHEs) have been
commissioned in line with allocation of funding detailed
above. The Care and Support PHE reported here has
developed a multi-centred, two phase mixed-methods
international study protocol. We report the protocol to
provide access to the full study methods [15], and to
offer examples of our responses to the methodological
challenges of conducting longitudinal multi-methods
and multidimensional research.
Methods/Design
Aims and objectives
This PHE has two aims. These are as follows. Aim 1) To
describe the nature and scope of HIV care and support
in two African countries, including the types of facilities
available, clients seen, and availability of specific compo-
nents of care [Study Phase 1]. Aim 2) To determine
patient health outcomes over time and principle cost
drivers [Study Phase 2].
The study objectives are as follows. 1) To undertake a
cross-sectional survey of service configuration and activ-
ity by sampling 10% of the facilities being funded by
PEPFAR to provide HIV care and support in Kenya and
Uganda (Phase 1) in order to describe care currently
provided. 2) To conduct patient focus group discussions
at each of these (Phase 1) to determine care received. 3)
To undertake a longitudinal prospective study of 1200
patients who are newly diagnosed with HIV or patients
with HIV who present with a new problem attending
PEPFAR care and support services. Data collection
includes self-reported quality of life, core palliative out-
comes and components of care received (Phase 2). 4)
To conduct qualitative interviews with staff, patients
and carers in order to explore and understand service
issues and care provision in more depth (Phase 2). 5)
To undertake document analysis to appraise the clinical
care procedures at each facility (Phase 2). 6) To deter-
mine principle cost drivers including staff, overhead and
laboratory costs (Phase 2).
Methods/Design
The study has a mixed methods design across two
Phases.
The first Phase utilises survey methods, focus group
discussions, document analysis and pharmacy checklist
review among a randomly selected stratified sample of
all HIV facilities receiving PEPFAR funds in Kenya and
Uganda.
The second Phase at each site employs qualitative
interviews with patients, family caregivers and staff,
longitudinally applied outcome tools among patients in
each of 12 facilities across Kenya and Uganda, and a
costing study.
The study protocol is depicted in Figures 1 and 2
Protocol development
Kenya and Uganda are two of the 15 PEPFAR ‘focus
countries’. They are both low-income countries with a
high prevalence of HIV, and are countries with public
health systems that may offer lessons for replication in
other African countries.
The PEPFAR programme is country-wide in the two
countries engaged in this PHE (and had been implemen-
ted for several years before the evaluation was commis-
sioned. Therefore it was not possible to conduct a
‘before and after’ study. One potential study design
option was to compare outcomes at facilities receiving
PEPFAR funding with those which did not, but there
are few large facilities in the target countries which have
never received PEPFAR funding, and they would have
little motivation to participate. Little information exists
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regarding the quality of life of general populations,
which could have been used as a comparison sample.
Further, facilities did not have stated targets against
which their performance could be compared.
A cross-sectional study would only be able to identify
differences between facilities, which might be caused by
population factors as well as variations in care and sup-
port delivery.
Therefore, a longitudinal cohort study design has been
selected to allow the effect of care over time to be exam-
ined. This design offers the most feasible and robust
option for evaluation of outcomes, although it is not pos-
sible to remove the effects of previous contact with
PEPFAR Care and Support.
Patient self-reported health has been selected as the
outcome of interest because care and support aims to
improve quality of life, and could not be properly
assessed without measuring this outcome. A mixed-
methods design incorporating both quantitative and
qualitative methods allows triangulation and greater
understanding of the data and its context.
This evaluation of PEPFAR-funded care and support
for HIV is led by King’s College London (KCL, Principal
Investigator), in collaboration with MEASURE Evalua-
tion at the University of North Carolina (UNC),
the African Palliative Care Association (APCA) and
the Kenyan Hospice and Palliative Care Association
(KEHPCA). The aims, methods and implementation of
the evaluation have been planned and agreed in consul-
tation with the members of United States Government
(USG) Care and Support Technical Working Group,
Kenyan and Ugandan PEPFAR Country Teams, and
representatives of the Ministries of Health in Kenya and
Uganda.
Ethical approval and procedures
Ethical approval to undertake the study has been
received from the Ugandan National Council for Science
Figure 1 Study flow chart for Phase 1: Structured descriptive analysis of facility configuration and activity.
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and Technology (UNCST, Ref SS 1964), the Kenyan
Medical Research Institute (Ref KEMRI/RES/7/3/1) and
the College Research Ethics Committee at KCL (Ref
CREC/06/07-140). Subsequent tool changes following
initial piloting have also been approved.
During longitudinal data collection, all questionnaires
are stored separately from consent forms, in a locked fil-
ing cabinet at the facility. Upon completion of the study,
anonymised questionnaires are taken from the facility to
the APCA offices for storage in locked filing cabinets.
These arrangements are in line with ethical guidance
and the UK Data Protection Act 1998. Interview tran-
scripts are stored without any identifying information
and names etc are deleted from the transcript. Original
digital recordings are deleted once transcribed. All study
computers are password protected.
Phase 1 methods
Sampling
Of around 600 PEPFAR-funded HIV care facilities in
each country, 60 have been selected for inclusion in the
study (approximately 10% of PEPFAR-funded facilities).
The inclusion criterion for eligibility in Phase 1 are that
they receive PEPFAR funding to provide HIV care and
support. The exclusion criteria are facilities that are pae-
diatric-only or inaccessible (e.g. insecure, no road
access). Facilities which do not meet the criteria above
were replaced using the same random process (and
replacements reported against the criteria).
According to routine monitoring patient numbers, the
PEPFAR-funded care and support facilities include
many smaller facilities. In order to capture a range of
Figure 2 Study flow chart for Phase 2: Longitudinal outcome evaluation.
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facility sizes within the study population, facilities were
stratified by number of patients seen for HIV care in
the previous financial year (according to national PEP-
FAR records) and divided into three strata (1 to 100,
101 to 500 and >500 patients seen), resulting in unequal
and calculable sampling fractions. Twenty facilities were
randomly sampled within each of the strata for the
study population.
Tool development & data collection procedure
All tools were developed by a multidisciplinary team,
including medical professionals, expert HIV researchers
and programmers, in conjunction with USG Care and
Support Technical Working Group and the PEPFAR
country teams. All tools have been piloted in one large
and one small Phase 1 facility in Uganda. These facilities
were two of the 60 selected, and data from the pilot uti-
lised in the final analyses. Following piloting, the wording
and structure of the tools were modified and clarified.
Facilities are informed of the planned survey through
the Ministry of Health (MOH) and invited to partici-
pate. Local African researchers attend each sampled site
to collect data on a pre-arranged day. Data are recorded
on two separate sets of identical forms. One set is left
with the facility while the other is taken by the research-
ers for data entry.
Four data collection tools are used.
Phase 1 data collection tool 1: Senior staff interview
The local researchers interview a group of senior staff,
including facility managers and senior clinical staff, at
each health facility to collect responses to closed and
open-ended questions about patient numbers, infra-
structure and staffing. This tool also includes a version
of the Client Services Receipt Inventory (CSRI) (Beec-
ham and Knapp 2001) adapted for the aims of this
study and the HIV setting in Africa to identify services
offered to patients with HIV. The CSRI asks if the facil-
ity offers various specific components of care under the
four domains of care: clinical, psychological, spiritual,
social and preventive. The tool is designed for use
across the wide range of size and type of HIV care facil-
ities funded by PEPFAR.
Researchers hold interviews with senior facility staff
(approximately three per facility, each contributing to a
single data collection form) to collect staff-reported
information on facility structure, service delivery, care
offered, and to ask their views about the services they
offer. These staff members are also asked to provide
blank service documents (including service aim, referral
forms, assessment sheets and patient information
sheets), where available.
Phase 1 data collection tool 2: Facility document collection
In order to study the level of patient-level clinical infor-
mation collection and management at each facility, the
existence, format and language of specific clinical docu-
ments relating to care in the facility are recorded (ser-
vice aim, inwards referral criteria, incoming/outgoing
referral forms, patient charging, ART protocols, care
protocols, first assessment sheets, ongoing contact
assessment sheets, patient records, referral follow-up
forms, stock control sheet, and information to patients).
Blank example documents are taken, where available,
for content analysis.
Phase 1 data collection tool 3: Pharmacy review
Researchers record the level and place of drug stock for
in-date and expired drugs separately, and if there had
been previous stockouts (in-date drugs only) for various
formulations of drugs commonly used in HIV care.
To complete the pharmacy review, researchers visit
the pharmacy to review stocks and stock cards and
complete the standard tables on current drug stocks,
stockouts, stock levels and access. This is conducted
with the assistance of the pharmacist (or dispenser or
other staff who worked in the pharmacy).
Phase 1 data collection tool 4: Patient focus group
discussions
Researchers lead patient discussion groups using the
semi-structured interview schedule. The focus group
discussions (FGD) have two main aims: to act as a vali-
dation of the senior staff interview data relating to com-
ponents of care offered, and to explore aspects relating
to patients’ care (e.g. which components of care are
valued and why, any problems in obtaining services).
FGDs are held with existing patients at each facility.
Inclusion criteria are as follows: adult patients who have
been under care for at least 6 weeks, who are known
(by both the patient themselves and clinical staff) to be
HIV positive and give informed consent to participate
(following provision of an information sheet and consent
form). Patients are purposively selected with the aim of
obtaining a diverse group with respect to gender, age,
disease stage and anti-retroviral (ARV) use.
Approximately five patients in each facility are invited
to participate in the discussion group, led by the
researcher. Researchers make notes on the responses to
pre-specified questions on the interview schedule, and
the FGD is digitally recorded as a back-up. During each
FGD, demographic information is collected on partici-
pants’ gender, location (urban, rural or peri-urban), age
and household size. Participants also state if they have
accessed specific key components of care including daily
cotrimoxazole (CTX), a mosquito bednet and nutritional
counselling.
Data management and entry
Data are transferred from Phase 1 facilities immediately
after collection. Quantitative data (i.e. closed questions
from the senior staff interview and the pharmacy review)
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are double-entered by two different researchers, and
validated, using EpiData v3.1. Errors in data entry and
data recording are identified using consistency and logic
checks, and followed-up by manual checking of ques-
tionnaires. Responses to open-ended questions and
FGDs are entered into pre-formatted templates in MS
Word 2003. Information from the record of documents
available at the facility, and their content, are entered
into tables in MS Word 2003 files.
Phase 1 analysis plan
Senior staff interviews
Analysis is conducted using Stata v10 (quantitative) and
NVivo v7 (open-ended questions). Frequency tables are
generated for key responses, grouped by facility type
where appropriate. A Spearman’s rank test for correla-
tion is conducted to test the reliability of routine data.
Patient numbers are weighted to account for the strati-
fied design used to select facilities. Thematic analysis of
content is conducted on the responses to the open-
ended questions [16]. The principal themes are orga-
nised into data categories and then agreed between two
researchers.
Facility document analysis
To determine the availability of the various types of ser-
vice documents, a matrix is developed to record the
number of facilities who report having each document,
and the number and percentage of facilities that pro-
vided examples for further analysis.
Where the percentage of facilities who provided exam-
ples of documents as a proportion of those who
reported such documents existed is less than 20%, or
where the absolute number of documents is five or
fewer, no further analysis is undertaken. Researchers
conduct telephone conversations with site representa-
tives in these cases to determine the reason for non-
provision.
In those instances where the percentage of facilities
who provide examples of documents as a proportion of
those who reported such documents existed was equal
to or greater than 20%, content analysis is undertaken.
Data are extracted to common tables, and frequencies
described for the number of facilities reporting each
type of recording sheet, whether a sample is obtained,
the specific nature of the information in the document
fields reported, and described according to facility type.
Pharmacy review
Analysis is conducted using Stata v10. Frequency tables
are generated for each drug, grouped by facility type
where appropriate. Data from the pharmacy review is
compared with components of care offered according to
the senior staff interview data in the CSRI.
Patient focus group discussions
Information on FGD participants’ background and
receipt of care items is entered into a predesigned table
by the researchers, transferred into an Excel spreadsheet
and then merged with the Stata database using a unique
identifying variable. The care received by FGD partici-
pants is integrated with the facility staff reports of care
offered.
Analysis of the FGDs text is conducted using NVivo
v7. In the same way as for the open-ended questions in
the senior staff interviews, thematic analysis of content
is conducted on the notes from the FGDs. The principal
themes are independently organised into data categories
and then agreed between two researchers.
Phase 2 Methods
Sampling procedure for Phase 2
Sampling health facilities
In Phase 1, the approximately 1200 facilities receiving
PEPAR Care and Support funding in Kenya and
Uganda were divided into three strata based on the
number of patients treated in the past year, and 20
facilities selected at random from each stratum within
each country. From these 60 facilities in each country,
the largest six in each were selected to participate in
Phase 2. The inclusion criteria for Phase 2, which
applied in addition to those for Phase 1, were that
facilities: recruited at least 30 new HIV patients a
month; had sufficient staff with essential skills to con-
duct data collection; offered ongoing care and support
to enable longitudinal data collection; had sufficient
capacity to engage in the research.
The six largest facilities in each country were selected
because they were the most likely to meet the inclusion
criteria listed above, and to remain engaged in the longi-
tudinal recruitment and data collection. Facilities were
informed of the planned survey and invited to partici-
pate through the Ministries of Health in each country.
Sampling patients
This Public Health Evaluation is not a trial, and does
not aim to observe an expected effect. Therefore the
Phase2 cohort study did not require statistically gener-
ated sample size calculation. The sample size of 100
patients per facility was selected based on the expected
number of new patients registered per month with ade-
quate follow-up data collection, and will be pooled at
the country level.
Consecutive patients who meet the following inclusion
criteria are approached for participation in the longitu-
dinal study: 18 years of age or over; diagnosed HIV posi-
tive; patient knows of their diagnosis; has sufficient
cognitive ability to answer the questions for the study;
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new to service or presenting with a new problem (social,
psychological, spiritual or physical).
Participants give informed consent to participate fol-
lowing provision of an information sheet and consent
form. These documents have been translated into local
languages in Uganda (Kiswahili, Dholuo, Runyakitara
and Luganda), and Kenya (Kiswahili, Dholuo). Informa-
tion and consent form are read aloud by the health care
worker for nonliterate prospective participants. Partici-
pants are reimbursed travel expenses to the facility of
US$5 per research interview visit. Each of the 12 facil-
ities recruits 100 participants.
Data collection tools and procedure
Qualitative interviews
At each facility, seven patients, three family caregivers
and five staff are invited to interview. The purposive
sampling strategy includes a variety of staff designations
with direct patient contact. Eligible participants for the
patient qualitative interviews are patients of the facility
who have been diagnosed as HIV positive, over 18 years
of age, been under care for at least six weeks, and are
not involved in the longitudinal study. These patient
participants are asked for consent to approach an identi-
fied adult informal carer (i.e. family member or friend
who provides assistance/support).
Patient, carer and staff participants give informed con-
sent to participate following provision of an information
sheet and consent form, which is read aloud to the
interviewee by the health care worker if the interviewee
is non-literate.
The semi-structured Interview schedules are designed
to gain greater understanding of service use, provision
and experiences from the views of the patients, their
informal caregivers and the facility staff. The principal
themes of enquiry within the schedules for patients and
carers are experience of facility care, choice of facility,
the nature and content of clinical encounters, and princi-
pal needs. Within the interviews, the full range of medi-
cal, psychological, spiritual and social domains are
addressed. Initial interview transcripts will be reviewed
and the topic guide revised where needed to improve
clarity of questions and fully explore key issues and any
emerging themes. The interview schedules, information
sheets and consent forms have been translated into local
languages from the English versions twice, independently,
by two local researchers. Each of these versions has been
translated back to English by a third researcher, with any
discrepancies discussed amongst the group and an agreed
translation decided.
Qualitative interviews with staff members, patients and
informal carers are conducted in private (usually in con-
sulting rooms at the care facility) in local languages as
indicated above, and digitally recorded.
One facility is located in a remote part of Uganda
where the most widely spoken local language is nationally
very rare, and spoken by none of the study researchers.
Rather than exclude an entire ethnic group from this sec-
tion of the evaluation, the patient and carer interviews
are conducted by a member of facility staff trained in
qualitative interviewing, with the researcher present.
Longitudinal quantitative study
The data collection tools in the Phase 2 longitudinal
study are four questionnaires, one of them (demography)
used only once per participant and the others (validated
tools) used four times at monthly intervals. The time
points, each one month apart, are designated T0 (entry
to the study), T1, T2 and T3. A ‘patient pack’ has been
created for data collection, consisting of all the tools
bound in the order they should be used, with the pages
colour coded by time point, and preceded by a log page
to complete the dates of interviews and a front cover
with the patient’s ID number. For each facility, question-
naire packs have been prepared in two languages; English
and a common local language. Translation procedure for
the packs is the same as for qualitative interview
schedules.
Basic demographic and medical details are collected
using a brief questionnaire administered at T0 (recruit-
ment to study). Four clinical questions are asked at T1
(one month later): World Health Organization (WHO)
HIV disease staging, date and result of most recent CD4
test, and date of beginning ART. These items were
moved from T0 to T1 because in piloting, health staff
pointed out that the information would not be available
to new participants at T0, and the response rate to
these questions would be higher at T1.
The APCA African POS is an adapted version of the
original POS, which was developed at KCL to address
the multidimensional problems of patients with incur-
able progressive disease and subsequently adapted
around the world [17,18]. The African APCA POS was
developed and validated in ten centres in six Sub-
Saharan African countries in 2006 [19,20]. Its ten items
address the primary physical, psychological, emotional
and spiritual concerns of patients and families and
employs scoring methods appropriate for a range of lit-
eracy skills. The validation study demonstrated its prop-
erties included sensitivity to change, and it has high
levels of patient and clinician acceptability. The ECOG
is a clinician-rated single item measure of physical per-
formance, also at administered at all four time points
[21]. Scores range from 0 (normal activity) to 4 (unable
to get out of bed). The ECOG is the most widely used
performance measure [22].
The MOS-HIV is a very widely used quality of life
measure and has been culturally adapted to the Ugan-
dan HIV setting [23,24]. The 35 items address the
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domains of: role function; pain; physical functioning;
cognitive functioning; overall health perception; mental
health; vitality. The weighted subscores in these domains
are then combined to produce two summary scores
measuring physical health and mental health.
A version of the Client Services Receipt Inventory (CSRI)
[25] has been adapted for the aims of this study and the
HIV setting in Africa in order to collect information about
services received by patients in the study. The CSRI
records receipt of 52 components of physical, psychologi-
cal, spiritual, social and preventive care, and whether they
were received at the facility or from elsewhere.
With the exception of CD4 counts, data for the longi-
tudinal quantitative study are self-reported by the partici-
pants, and recorded in the questionnaire packs provided
by health care workers (HCWs) already employed at each
facility.
HCWs are trained in the process of seeking informed
consent and the completion of the questionnaires. A
researcher maintains contact with each facility through
regular visits including observing data collection, check-
ing the use of appointment diaries and regular data
entry, and delivering additional training as necessary.
Data collection (i.e. at recruitment (T0) and at three
subsequent interviews a month apart) coincides with
clinical appointments where possible. Once participants
complete the longitudinal study, CD4 counts are
extracted from patient records by the HCWs, or by the
researchers themselves under the supervision of HCWs.
Piloting demonstrated that participants often could
not remember the date and result of their last CD4
count. Accordingly, permission was granted by the
ethics board overseeing the study to search patients’
records for CD4 counts. Therefore, researchers visit
each facility and transcribe CD4 counts for the study
participants from their file into a specially designed
form which preserves anonymity while allowing records
to be linked to participants. CD4 count is the only vari-
able data obtained in this way. The decision to refer to
patient records was taken because the researchers knew
the information was collected by facilities, and partici-
pants had been informed of their result, but they simply
could not remember the information.
One questionnaire pack contains all the data sheets for
one individual. The pages are colour-coded to indicate
time points. The front cover of the pack is blank apart
from the patient’s name. When the final time point is
complete, this page is torn out and destroyed, making the
data unidentifiable. The second page includes metadata
logging the progress of data collection and management
for each time point.
Costing items
Because the provision of care is a complex area of investi-
gation, there are potentially a number of cost components
that could be accounted for. Due to the constraints of this
large multi-methods study (of which economics are a
component rather than the primary outcome of interest),
the following key cost drivers are examined: labour (by
staff type, staff salaries); medicines (ARVs, pain medicines,
antibiotics, other) and their inventories (buffer stock);
laboratory items (supplies and equipment); buildings
(assigned market value or annual rent cost) and utilities;
capital inputs (high end equipment and vehicles).
Because only the major cost drivers are included, the
costs in this report are likely to be an underestimate of
the real costs of providing care. Cost elements that may
be significant, but which are not accounted for include:
costs of developing training programmes, training of
health providers, supervision, monitoring and evaluation
including health information management, clinic admin-
istrative costs, drug and commodities management and
maintenance and depreciation on capital assets.
As HIV care and support is provided in a clinical set-
ting in which other non-HIV services are provided, it is
necessary to estimate the proportion of some cost ele-
ments which are measured for all clinical services and
attribute a share for HIV care and support. This is a
common issue with the costing of services that are pro-
vided in an environment where several medical special-
ities are simultaneously provided separately at one
facility. For labour costs, the proportion of time that
staff are involved in providing care and support services
is used to calculate the fraction of labour costs allocated
to care and support.
Capital and building costs are allocated to HIV care
and support using the proportion of all patients
accounted for by HIV patients. Similarly, drug costs that
are not ARVs and not for analgesia (opioids and non-
opioids) are allocated to HIV care using the same propor-
tion. Tools have been piloted and revised to maximise
validity of the data collected, and for ease of data provi-
sion among facilities.
A data collection instrument was designed and tested
to capture the identified cost elements in each of the
Phase 2 facilities. Facility level data includes number of
patients seen by staff category in a typical day, hours
spent with HIV patients per week and hours worked per
week by staff category; number of staff by category
involved in HIV care; quantities of medications dis-
pensed in the previous three months by drug type; num-
bers of laboratory tests conducted in the previous three
months; information on physical buildings such as space
and an equivalent in rental value of the space; utility
costs per month including water, electricity, generator
fuel, communications, waste disposal etc.; transport
costs, fuel, costs of drivers, maintenance; clinical con-
sumable costs per month (including gloves, syringes,
cotton wool swabs, plasters, soap, sterilizing solution
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etc); amount spent on volunteer staff including training,
travel reimbursements, payment in kind in previous
three months.
Researchers gather the information required for the
instrument with information provided by key informants
at each facility. Key informants vary by facility but gen-
erally include the hospital administrator or manager, the
accountant, clinicians, nurses and pharmacists. More
than one site visit is undertaken in order to interview all
relevant respondents and to complete the questionnaire.
Unit costs are required for some cost elements. These
include staff (i.e. full salaries including allowances),
prices of medicines and unit costs of laboratory tests.
Salaries are obtained from each site and were average
levels paid for each staff category. Drug costs are largely
obtained from international sources such as the WHO
and the International Drug Price Indicator Guide [26]
while laboratory test costs are obtained from ATC [27].
Data management and entry
Phase 2 Qualitative interviews
Interview recordings are transcribed verbatim into MS
Word 2003 in the language in which they are con-
ducted. If the interview is not conducted in English, two
independent translations into English are then per-
formed, either by the researchers or by experts from the
Department of Linguistics at the local Institute of Psy-
chology. A team of three then reconcile the two inde-
pendent translations, referring back to the recorded
interview if necessary, and agree upon a final version.
For the three interviews conducted by a health worker,
a team of three health workers at the facility translate
the recordings into English, and a native-speaker linguist
checks the transcript while listening to the tape. After
the final translations are agreed, the recordings are
destroyed.
A table containing demographic information on the
participant is added to the beginning of each transcript.
These data are extracted from interviews and subse-
quently entered into Excel tables.
Phase 2 Longitudinal quantitative data
Immediately after collection, data are entered into a pre-
designed EpiData v3.1 database with conditional checks
for internal consistency. Data entry is conducted at the
health care facility by an administrative staff member
trained in the use of the tools and the database. When
participants have completed the final data point, the
completed data collection tools are transferred to the
local central research office. There, the research staff
conduct a second round of all data entry and validation
of both rounds of data entry. Discrepancies identified
are corrected by manual checking of questionnaires, and
results revalidated until the two datasets are identical.
The CD4 information from patient records is entered
into a separate EpiData database and merged into the
main dataset.
Phase 2 Costing items
The data are entered into predesigned Excel spread-
sheets. Analysis, including creation of graphs and linear
regression, is conducted in Excel workbooks with data
drawn together from the different sheets.
Phase 2 Analysis plan
The three main sources of data (longitudinal quantita-
tive study, qualitative interviews and costing) are ana-
lysed separately. Analysis plans for each data component
are outlined below.
Qualitative interviews
The interview verbatim transcripts are imported from
Word into NVivo 7 for coding and analysis. Information
on interviewees’ age, gender, household location, family
size, profession (for staff), whether they were receiving
ART (for patients) and relationship to patient (for
carers) are extracted into an Excel table, subsequently
imported into NVivo. Identifying information such as
names of individuals or care facilities are removed from
transcripts. Thematic analysis of content is conducted
concurrently on the patient, carer and staff interviews to
enable multiple perspectives on each coded theme.
Three coding frames are developed and subsequently
combined into a single version applied to the transcripts
for the remainder of the coding. One coding frame is
developed in Uganda by the team of local researchers
who had conducted the interviews, and a second by the
Kenyan researchers. The third coding frame is devel-
oped at KCL in London. The intention is to explore
cross-cultural differences and similarities in coding, and
to generate a definitive coding frame that reflects local
understanding of the data and scientific rigour.
In each three-person country research team, every
researcher codes nine randomly selected interviews
(three with a patient, three with a member of staff and
two with a carer), creating hierarchical codes. The local
team members agree on a coding frame by discussion,
comparison and consensus. The three teams then meet
and a unified coding frame is developed, combining the
strengths of each country-level frame. Each code is
reviewed for internal consistency and given an agreed
definition to ensure it is applied using a standard mean-
ing by each researcher. The researchers are trained in
the use of NVivo 7 and in application of the new coding
frame, which is applied to the entire dataset.
Quantitative longitudinal patient data
The primary outcomes are the physical and mental
health summary scores derived from the MOS-HIV.
Secondary outcomes are individual POS item scores,
and a combined total POS score. Individual POS item
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scores are not expected to be parametric and are sum-
marised using the median and inter-quartile range. A a
p-value of 0.05 will be used to determine significance in
all statistical tests except for the decision to include
variables in multivariate analysis, when 0.1 will be used.
Initial cross-sectional descriptive analysis of the data will
be conducted first.
Time points will be compressed and recoded if neces-
sary to make the most efficient use of the data. For
example, if a participant is recorded to have completed
T0, T2 and T3 but missed T1, then T1 is deleted from
the record and T2 and T3 renumbered T1 and T2, to
obtain a continuous series of three points.
Clinical variables (CD4 count, HIV disease stage, phy-
sical function) and demographic characteristics (age,
gender, location of home, education, number of depen-
dants) of participants will be described for the total
sample and by country and facility. Variables relating to
socioeconomic status will be incorporated into a princi-
pal components analysis to generate a single factor, and
this will be split into quintiles of relative wealth [28].
For univariate analysis of demographic/clinical charac-
teristics with primary outcomes at baseline, ANOVA
will be used for ordinal variables and linear regression
for continuous.
The 52 components of care recorded in the CSRI will
be grouped into care themes according to the issues
they address and the way in which they are delivered.
Care themes are listed following.
Spiritual: visit by a religious leader, prayer with
patients, and contact with traditional healer. Spiritual
care is a distinct aspect of palliative care. Staff praying
with patients, and a visit from a religious leader, are the
most common types of spiritual care provided through
health facilities. Many people with HIV visit traditional
healers [29] and the care delivered by them fits the PEP-
FAR definition of spiritual care being sensitive to indivi-
dual and community culture [30].
Counselling and advice: pre-and post-test counselling,
adherence counselling, family planning counselling,
patient HIV support groups, family counselling and psy-
chiatric therapy. This theme comprises all ‘talking thera-
pies’. It is sometimes difficult to distinguish counselling
as listening and responding to the patient’s worries and
concerns from counselling as didactic imparting of
information. VCT, for example, is a strategy of both pre-
vention and care, assessed for its efficacy in reducing
risk behaviour and HIV transmission [31].
Nursing: wound care and other nursing care.
Pain management: assessment of pain and provision of
strong and weak opioids or non-opioid analgesics and
treatment for neuropathic pain.
Pain is a common symptom in HIV [32] and all five
components in this group are necessary for its relief.
The WHO pain ladder [33] outlines the need for non-
opioid and opioid analgesics until pain has been con-
trolled. Neuropathic pain, which is particularly common
in HIV [34] is caused by damage to nerves and does not
respond to traditional pain medication.
Symptom management: treatment for anxiety/depres-
sion, nausea/vomiting, skin rash/itching, diarrhoea, laxa-
tives, thrush, oral candidiasis, cryptococcus, other fungal
infections, herpes, malaria and other opportunistic infec-
tions. The components in this theme were usually
defined by the symptom treated, rather than the under-
lying cause or pathogen, because the cause of a symp-
tom is often not known in HIV disease [35]. All these
physical symptoms and conditions are common in
HIV [35,36].
Nutrition: food, multivitamins, nutritional advice, safe
drinking water, therapeutic feeding for malnutrition.
Poor nutrition comprises two problems: lack of macro-
nutrients (wasting, malnutrition) and lack of micronutri-
ents (vitamins and minerals). Both of these predispose
individuals with HIV to infections and ill health. Lack of
food is the most fundamental level of poverty.
Social: employment training/income generating activ-
ities (IGA), home help, household items, legal services,
memory book work, loans/microfinance. The social
group components were selected after advice from USG
country mission teams. Memory book work was allo-
cated to the social care group because it aims to reduce
internalised stigma and improve relations between
family members.
Prevention: prevention with positives, condoms, ITNs,
infection control training, isoniazid for TB prophylaxis.
This care group includes both components to protect
the person with HIV from other infections, and compo-
nents to prevent them from infecting others with HIV.
Prevention with positives is the general name for a
package of care designed to encourage behaviour change
(condom use, reduction of partners, and revealing HIV
status). Condoms prevent further infection and also pro-
tect the individual from other strains of HIV and from
other STIs such as herpes. Insecticide-treated nets pro-
tect against malaria, which is more common and more
aggressive in people with HIV [37], and the TB drug
isoniazid can be used as a prophylactic for those at high
risk of TB.
ART: ARVs and assessment of ARV treatment. Antire-
troviral therapy includes regular assessment to observe
signs of developing resistance, toxicity and side effects.
CTX: daily CTX. PEPFAR guidelines encourage daily
CTX prophylaxis for everyone with HIV. It is a broad-
spectrum antibiotic proven to reduce morbidity and
mortality in people with HIV [38,39]. At each interview
participants are asked whether they had taken CTX on
the previous day and whether they had been given daily
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prophylactic CTX in the last month. These answers are
compared to test adherence.
TB: TB treatment. TB treatment is listed separately
from treatment for other symptoms and infection, for
two reasons. Firstly, it is the leading cause of death for
people with HIV in Africa [40]. Secondly, the course of
treatment lasts for four to six months, long after symp-
toms have resolved. The full course of treatment must
be completed to prevent resistance and recurrence.
Baseline outcomes, demographic variables and care
theme delivery will be compared between the facilities.
To test the hypothesis that participants who receive
antiretroviral therapy or TB treatment at T1 (a month
after recruitment) are likely to have more advanced dis-
ease, physical and mental health, and CD4 count, will be
compared for recipients and non-recipients using t-tests.
Physical and mental health outcomes will also be com-
pared for those who attend with and without a carer, to
test the hypothesis that carers are more likely to accom-
pany those in poorer health.
The longitudinal outcome analysis will be conducted
as follows. Mean and 95% confidence intervals for physi-
cal and mental health score are plotted over time as a
graphical representation of change in health states.
Longitudinal multilevel modelling is an approach
which makes the most efficient use of data collected
over time. Unlike most statistical tests, it includes all
time points at once, which both reduces the number of
tests to be carried out (making false positive results
less likely) and allows change to be modelled as a con-
tinuous effect. This means that rather than simply
finding variables which are associated with any change
in outcome, the magnitude of the change can also be
considered.
A common problem in longitudinal studies of health
outcomes is that patients with the worst health are the
most likely to leave the study and be lost to follow-up,
so that a comparison between the beginning and end of
the study could find improved outcomes only because a
proportion of those with poor health would not contri-
bute to the later timepoint. Longitudinal analysis does
not have this bias because all participants can be
included whether they complete the study or not. Addi-
tionally, longitudinal analysis can reveal patterns over
time which would not be identified using traditional
methods.
The technique adopted in this study was multilevel
mixed-effects linear regression, selected because it
allows data to be clustered at two levels, by individual
and by facility [41]. Many longitudinal studies suffer
from the bias caused by the most unwell individuals
being most likely to leave the study. To determine
whether this bias was present, t-tests are used to com-
pare the mean physical and mental health scores of
those who completed all four observations with those
who missed at least one. Traditional analysis of longitu-
dinal data involves comparing the earliest observation
with the last, so any difference in the scores of comple-
ters versus non-completers would bias the findings.
In addition, the same tests are used to compare the
mean scores of those who only completed a single
observation with those who completed two or more.
This is to test the suitability of multi-level modelling,
which is explained below. Multi-level modelling uses all
data points except the first one, so anyone who only
completed one observation would be excluded and it is
necessary to test whether this would also cause a bias.
For the same reason, mean change over time is reported
as the mean of all individual score changes, rather than
mean health score at one time point subtracted from
mean health score at another.
Multilevel modelling is carried out using the Stata
xtmixed command function. Outcomes are physical
health score and mental health score, measured up to
three times at monthly intervals. Baseline score is incor-
porated as a covariate and not as an outcome. Models
included levels for facility and individual. The only ran-
dom effect is time point (interview number, rather than
actual time interval), which is allowed to have a random
coefficient at the individual level. Other covariates are
fixed. Demographic and care theme covariates are con-
stant over time, receipt of ART and TB treatment var-
ied. The default independent covariance structure is
used. Variance and standard error of variance are
reported for random-effects parameter estimates.
This analysis is repeated with the 20% of participants
who had the lowest physical health score at T0, and
with the 20% who had the lowest mental health score at
T0, to determine whether the effect of improved out-
comes over time extended to those in greatest need. For
the APCA African POS, score distribution at each time-
point is tabulated for those who scored 0 (worst possible
problem) on the items relating to pain and symptoms.
This simple approach is adopted because a very few
people scoring 0 on these items could introduce bias.
The items for pain and symptoms are selected because
people with complex, intractable problems in advanced
disease may not experience improvement although aver-
age scores for the population increase.
The multilevel models will be repeated several times,
each time with the addition of a single demographic
covariate. Models will also be developed with ART
receipt and TB treatment, which will vary over time.
Examining the relationship between health outcomes
and care received is complicated by the potential bias
that those in the worst health would probably receive
the most care, whereas a lack of care could mean either
no need of it, or lack of appropriate provision. To avoid
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this problem, a variable representing available care is
required, which might have a closer association with
health outcomes than the level of care individually
received. Availability of care is defined as the percentage
of individuals at a facility who receive care in a particu-
lar theme. Care themes are used rather than individual
components in order to reduce the number of variables
needed in the model and ensure stability. For example,
the variable ‘psychological care’, contains information on
the percentage of people, per facility, who receive at
least one component of psychological care at T1, T2 or
T3. T0 is excluded because the model analyses change
from T0 onwards.
Each of the care themes is included one by one in a
univariate multilevel model as described above; with the
difference that care theme has only twelve values, one
for each facility, and does not change over time.
Following this, all individual-level and facility-level
covariates associated with outcome at the 10% level in
univariate analysis are taken forward into a multivariate
model and eliminated in a downward stepwise proce-
dure if the association is lost. It is usual to use 10% as
the acceptance level with stepwise downward regression
to avoid dismissing variables too early.
Costing study
The purpose of the costing survey is to develop under-
standing of the factors which influence per-patient costs,
and to guide resource allocation, for example by observing
economies of scale. Analysis is conducted using an Excel
spreadsheet. Most data are collected in local currency
(Kenyan and Ugandan shillings), and converted to US dol-
lars at the current exchange rates. Since only twelve facil-
ities are included and these facilities were not meant to be
representative of all sites, all results are reported per facil-
ity without aggregation across the sample. The average
costs per patient for one year of care and support are cal-
culated using aggregated average costs per patient for each
of the main components of care for a year.
Data integration
The final step of analysis is the integration of The Phase
1 and Phase 2 data are integrated to enable the outcome
and cost data to be appraised in the light of the facility
configuration data
Discussion
This substantive study will provide novel data to inform
the provision of HIV care and support programmes in
Sub-Saharan Africa. The dual phases and mixed meth-
ods allow triangulation and integration of diverse types
and sources of data to better determine patient out-
comes and factors associated with patient and family
experience of HIV care.
We believe that there are several elements to the
design and implementation of this protocol that are ori-
ginal and offer methodological advantages. Firstly, the
aims objectives and associated data collection tools have
been informed by a large collaboration between practi-
tioners, policy and programme designers, implementing
partners, academics and Ministry of Health representa-
tives across 3 continents. This has greatly improved the
potential data demand and utilisation of the study. Sec-
ond, all research staff involved in data collection and
working with facilities are indigenous African research-
ers, and considerable capacity has been built through
ongoing training and the conduct of this large study.
Third, the novel mixed methods approach brings
together an integrated mixture of outcome measure-
ment, longitudinal evaluation, qualitative approaches,
health economics, document analysis and drug availabil-
ity review to evaluate HIV care and support. Fourth, the
careful attention to multiprofessional inclusivity and
consultation, and piloting of tools, has maximised the
feasibility of this study where many logistical challenges
are presented [42]. We have encountered ethnic and
political violence and unrest, lack of available transport
to some regions, and temporary closure of services to
patients, although these challenges have been overcome.
Fifth, we have paid considerable attention to data
demand and utilisation, which has encouraged us to
initiate processes of consultation and feedback at each
stage of protocol design and to identify the data needs
of our stakeholders. Sixth, we have been clear that this
evaluation does not aim to compare outcomes between
facilities or countries (e.g. to identify facilities perform-
ing less well), as it is important to encourage participa-
tion in this type of outcome evaluation without
introducing objectives that may be interpreted as critical
or competitive. We have generated a regular study
newsletter to promote communication and information
flow between research sites and partners. Seventh, we
have also taken steps to reduce potential bias in the
methods, for example by forward and back translation
of tools and selection of person-centred outcome tools
that have been locally validated. Our analytical proce-
dures have attempted to identify bias commonly identi-
fied in this type of data for example by potential
attrition of the sickest, and the use of longitudinal
approaches that maximise use of the data. Error has
been reduced through double entry of all quantitative
data and careful translation of qualitative data. Lastly,
we offer reimbursement to participants of $5 for each
research interview, which is felt to not be large enough
to be seen as an unethical inducement to participate in
the study, but is enough to comfortably cover costs of
attending additional research interviews. The use of pay-
ments to take part in longitudinal research in low
Harding et al. BMC Public Health 2010, 10:584
http://www.biomedcentral.com/1471-2458/10/584
Page 12 of 14
income countries is advocated, not least due to emer-
ging evidence that a key reason for non-adherence to
ART is inability to afford to attend HIV clinics [43-45].
Analysis is currently underway. We believe that the
presentation of this protocol offers greater transparency
in the aims, objectives and analysis of our study, and
will permit greater focus on the reporting of our large
dataset.
Acknowledgements
We are grateful to the United States Agency for International Development
for funding this study under a sub-agreement GPO-A-00-03-00003-00, made
under the authority provided to the University of North Carolina. The
present study benefited from the participation of a wide range of partners,
medical professionals, HIV specialists and palliative care researchers. The
authors are grateful for the guidance provided by the United States
Government Palliative Care Technical Working Group and to the Kenyan and
Ugandan Country Teams. Finally we are grateful to the staff and patients at
the participating facilities.
Author details
1King’s College London, Cicely Saunders Institute Department of Palliative
Care, Policy and Rehabilitation School of Medicine at Guy’s, King’s and St
Thomas’ Hospitals Bessemer Road, London SE5 9PJ, UK. 2King’s College
London Department of Health Service and Population Research Institute of
Psychiatry Box P024, De Crespigny Park London, SE5 8AF, UK. 3Futures Group
One Thomas Circle, NW, Suite 200 Washington DC 20005, USA. 4African
Palliative Care Association PO Box 72518 Kampala, Uganda. 5University of
Aberdeen Department of Public Health, School of Medicine Polwarth
Building Foresterhill, Aberdeen AB25 2ZD, UK. 6MEASURE Evaluation Project
Carolina Population Center University of North Carolina at Chapel Hill, CB
8120 Chapel Hill, NC 27599, USA.
Authors’ contributions
The Principal Investigators are RH and IJH. All authors contributed to the
design and protocol development. All authors have read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 August 2010 Accepted: 29 September 2010
Published: 29 September 2010
References
1. UNAIDS: HIV and AIDS estimates and data, 2007 and 2001 from the
2008 report on the global AIDS epidemic. 2008.
2. Bendavid E, Bhattacharya J: The President’s Emergency Plan for AIDS
Relief in Africa: an evaluation of outcomes. Ann Intern Med 2009,
150:688-695.
3. Reynolds HW, Janowitz B, Wilcher R, Cates W: Contraception to prevent
HIV-positive births: current contribution and potential cost savings in
PEPFAR countries. Sex Transm Infect 2008, 84(Suppl 2):ii49-ii53.
4. Collins K, Harding R: Improving HIV management in sub-Saharan Africa:
How much palliative care is needed? AIDS Care 2007, 19:1304-1306.
5. Sherr L, Lampe F, Fisher M, Arthur G, Anderson J, Zetler S, et al: Suicidal
ideation in UK HIV clinic attenders. AIDS 2008, 22:1651-1658.
6. Antelman G, Kaaya S, Wei R, Mbwambo J, Msamanga GI, Fawzi WW, et al:
Depressive symptoms increase risk of HIV disease progression and
mortality among women in Tanzania. J Acquir Immune Defic Syndr 2007,
44:470-477.
7. Chipimo PJ, Fylkesnes K: Mental distress in the general population in
Zambia: impact of HIV and social factors. BMC Public Health 2009, 9:298.
8. Rosen S, Ketlhapile M, Sanne I, Desilva MB: Differences in normal activities,
job performance and symptom prevalence between patients not yet on
antiretroviral therapy and patients initiating therapy in South Africa.
AIDS 2008, 22(Suppl 1):S131-S139.
9. Koethe JR, Chi BH, Megazzini KM, Heimburger DC, Stringer JS:
Macronutrient supplementation for malnourished HIV-infected adults: a
review of the evidence in resource-adequate and resource-constrained
settings. Clin Infect Dis 2009, 49:787-798.
10. Beadles WI, Jahn A, Weigel R, Clutterbuck D: Peripheral neuropathy in HIV-
positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop Doct
2009, 39:78-80.
11. Wakeham K, Harding R, Bamukama D, Levin J, Kissa J, Parkes R, et al:
Symptom burden in HIV infected adults at time of HIV diagnosis in rural
Uganda. Journal of Palliative Medicine 2010, 13:375-380.
12. Harding R, Powell RA, Kiyange F, Downing J, Mwangi-Powell F: Provision of
pain and symptom-relieving drugs for HIV/AIDS in Sub-Saharan Africa.
Journal of Pain & Symptom Management 2010, 40:405-415.
13. Feitsma AT, Koen MP, Pienaar AJ, Minnie CS: Experiences and support
needs of poverty-stricken people living with HIV in the Potchefstroom
district in South Africa. J Assoc Nurses AIDS Care 2007, 18:55-64.
14. Selman L, Higginson IJ, Agupio G, Dinat N, Downing J, Gwyther L, et al:
Meeting information needs of patients with incurable progressive
disease and their families in South Africa and Uganda: multicentre
qualitative study. BMJ 2009, 338:b1326.
15. Godlee F: Publishing study protocols. BMC News and Views 2001, 2.
16. Garcia J, Evans J, Reshaw M: “Is there anything else you would like to tell
us” - methodological issues in the use of free-text comments from
postal surveys. Quality and Quantity 2004, 38:113-125.
17. Hearn J, Higginson IJ: Development and validation of a core outcome
measure for palliative care: the palliative care outcome scale. Palliative
Care Core Audit Project Advisory Group. Qual Health Care 1999,
8:219-227.
18. Higginson IJ, Donaldson N: Relationship between three palliative care
outcome scales. Health Qual Life Outcomes 2004, 2:68.
19. Harding R, Selman L, Agupio G, Dinat N, Downing J, Gwyther L, et al:
Validation of a core outcome measure for palliative care in Africa: the
APCA African Palliative Outcome Scale. Health and Quality of Life
Outcomes 2010, 8:10.
20. Powell RA, Downing J, Harding R, Mwangi-Powell F, Connor S:
Development of the APCA African Palliative Outcome Scale. J Pain Symp
Manage 2007, 33:229-232.
21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. American Journal of Clinical Oncology 1982, 5:649-655.
22. Bowling A: Measuring Disease Buckingham: Open University Press, 2 2001.
23. Mast TC, Kigozi G, Wabwire-Mangen F, Black R, Sewankambo N,
Serwadda D, et al: Measuring quality of life among HIV-infected women
using a culturally adapted questionnaire in Rakai district, Uganda. AIDS
Care 2004, 16:81-94.
24. Stewart AL, Hays RD, Ware JE Jr: The MOS short-form general health
survey: reliability and validity in a patient population. Med Care 1988,
26:724-735.
25. Beecham J, Knapp M: Costing psychiatric interventions. In Measuring
Mental Health needs. Edited by: Thornicroft G. London: Gaskell; 2001.
26. International Drug Price Indicator Guide 2010. [http://erc.msh.org/
mainpage.cfm?file=1.0.htm&module=DMP&language=English], Accessed
July 2010.
27. ATC Labs: Argo - Tech Materials Laboratory. [http://www.atclabs.com/],
Accessed July 2010.
28. Gwatkin DR, Rustein S, Johnson K, Pande RP, Wagstaff A: Socioeconomic
differences in health nutrition and population in Ghana. World Bank.
HNP/Povery Thematic Group of the World Bank 2000.
29. Langlois-Klassen D, Kipp W, Jhangri GS, Rubaale T: Use of traditional herbal
medicine by AIDS patients in Kabarole District, western Uganda. Am J
Trop Med Hyg 2007, 77:757-763.
30. Office of the Global AIDS Coordinator: HIV/AIDS Palliative Care Guidance
#1 for the United States Government In-Country Staff and Implementing
Partners. U.S. Department of State 2006.
31. The Voluntary HIV-1 Counselling and Testing Efficacy Study Group: Efficacy
of voluntary HIV-1 counselling and testing in individuals and couples in
Kenya, Tanzania, and Trinidad: a randomised trial. Lancet 2000,
356:103-112.
32. Shawn ER, Campbell L, Mnguni MB, Defilippi KM, Williams AB: The
spectrum of symptoms among rural South Africans with HIV infection. J
Assoc Nurses AIDS Care 2005, 16:12-23.
Harding et al. BMC Public Health 2010, 10:584
http://www.biomedcentral.com/1471-2458/10/584
Page 13 of 14
33. World Health Organisation: Palliative care: symptom management and
end of life care. IMAI: interim guidelines for first-level facility health
workers in low-resource settings. [http://www.who.int/3by5/publications/
documents/en/genericpalliativecare082004.pdf], Accessed 27/09/10.
34. Paice JA, Shott S, Oldenburg FP, Zeller J, Swanson B: Efficacy of a vibratory
stimulus for the relief of HIV-associated neuropathic pain. Pain 2000,
84:296.
35. Welch JP, Barlow D, Richardson PH: Symptoms of HIV disease. Palliat Med
1991, 5:46-51.
36. Makoae LN, Seboni NM, Molosiwa K, Moleko M, Human S, Sukati NA, et al:
The symptom experience of people living with HIV/AIDS in Southern
Africa. J Assoc Nurses AIDS Care 2005, 16:22-32.
37. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al:
Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and
insecticide-treated bednets on the frequency of malaria in HIV-1-
infected adults in Uganda: a prospective cohort study. Lancet 2006,
367:1256-1261.
38. Pitter C, Kahn JG, Marseille E, Lule JR, McFarland DA, Ekwaru JP, et al: Cost-
effectiveness of cotrimoxazole prophylaxis among persons with HIV in
Uganda. J Acquir Immune Defic Syndr 2007, 44:336-343.
39. Grimwade K, Swingler G: Cotrimoxazole prophylaxis for opportunistic
infections in adults with HIV. Cochrane Database of Systematic Reviews
2003, CD003108.
40. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, et al:
Prevalence, incidence and mortality associated with tuberculosis in HIV-
infected patients initiating antiretroviral therapy in rural Uganda. AIDS
2007, 21:713-719.
41. Twisk JWR: Applied Longitudinal Analysis for Epidemiology: a practical guide
Cambridge: Cambridge University Press 2003.
42. Harding R, Powell RA, Downing J, Connor SR, Mwangi-Powell F, Defilippi K,
et al: Generating an African palliative care evidence base: the context,
need, challenges, and strategies. J Pain Symptom Manage 2008,
36:304-309.
43. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN,
Bangsberg DR: Adherence to HIV antiretroviral therapy in HIV+ Ugandan
patients purchasing therapy. Int J STD AIDS 2005, 16:38-41.
44. Diabate S, Alary M, Koffi CK: Determinants of adherence to highly active
antiretroviral therapy among HIV-1-infected patients in Cote d’Ivoire.
AIDS 2007, 21:1799-1803.
45. Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F, et al: Patterns
of individual and population-level adherence to antiretroviral therapy
and risk factors for poor adherence in the first year of the DART trial in
Uganda and Zimbabwe. J Acquir Immune Defic Syndr 2008, 48:468-475.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/10/584/prepub
doi:10.1186/1471-2458-10-584
Cite this article as: Harding et al.: Multi-centred mixed-methods PEPFAR
HIV care & support public health evaluation: study protocol. BMC Public
Health 2010 10:584.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Harding et al. BMC Public Health 2010, 10:584
http://www.biomedcentral.com/1471-2458/10/584
Page 14 of 14
